It is estimated that more than 85% of all cancers originate in the epithelium. Excision biopsy to remove tissue from the body and examining it under a microscope, is the gold standard for cancer diagnosis. TPI™ technology has the potential to greatly improve conventional biopsy and associated surgery by more precisely identifying the areas to be excised thereby reducing the number of procedures and facilitating earlier and more accurate diagnosis. As the technology matures, it may be possible to perform biopsies using TPI™ alone, making possible point of care optical biopsy
.
Uniquely TPI™ offers the ability to produce 3D images at high resolution through thick tissue using molecular markers, such as water, to provide spectral and absorption information to differentiate between cancerous and non-cancerous tissues, non-invasively and using non-ionising radiation.
TeraView is working closely with clinical customers and partners to provide imaging and spectroscopic capabilities from our instrumentation for tissue and disease classification ex vivo on excised tissue. We are also actively engaged with partners to develop in vivo intra-operative probes for tissue conservation surgery and endoscopic applications on patients. Extensive work has been carried out on skin and basal cell carcinoma, and recent clinical work has extended these capabilities to breast and other types of tissue.
Find out more about TeraView’s emerging terahertz imaging technology in oncology. |
